ReWalk RoboticsLFWD
LFWD
About: Lifeward Ltd is a medical device company that designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering functional and health benefits in clinical settings as well as in the home and community. Its product offerings are the ReWalk Exoskeleton, the ReStore Exo-Suit, the MyoCycle FES bikes, and AlterG Anti-Gravity systems. It operates through markets in the United States, Israel, and Germany.
Employees: 80
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
827% more call options, than puts
Call options by funds: $658K | Put options by funds: $71K
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
1.29% less ownership
Funds ownership: 3.05% [Q4 2024] → 1.76% (-1.29%) [Q1 2025]
30% less funds holding
Funds holding: 23 [Q4 2024] → 16 (-7) [Q1 2025]
31% less capital invested
Capital invested by funds: $465K [Q4 2024] → $319K (-$145K) [Q1 2025]
70% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 10
Research analyst outlook
We haven’t received any recent analyst ratings for LFWD.
Financial journalist opinion
Based on 4 articles about LFWD published over the past 30 days
Neutral
PRNewsWire
4 days ago
MedRhythms Appoints Larry Jasinski as Chief Executive Officer to Lead Next Phase of Growth and Commercial Expansion
Industry veteran with proven track record in neurorehabilitation and fundraising to lead next phase of growth; Co-founder Brian Harris transitions to Chief Scientific Officer PORTLAND, Maine , July 7, 2025 /PRNewswire/ -- MedRhythms, Inc., a company pioneering the development of next-generation neurotherapeutics to improve walking, mobility and related functional outcomes, and creator of the world's first prescription music platform, announced the appointment of Larry Jasinski as Chief Executive Officer, effective immediately. Co-founder of MedRhythms, Brian Harris, who led the company through product development, successful clinical trials, listing product with the Food and Drug Administration (FDA), and assignment by the Centers for Medicare and Medicaid Services (CMS) of a benefit category and unique Health Care Common Procedure Coding System (HCPCPS) code, will transition to the role of Chief Scientific Officer (CSO) and work with Larry to build the market and grow the company in its next phase.
Neutral
GlobeNewsWire
2 weeks ago
Lifeward Announces Closing of $2.6 Million Public Offering
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, June 26, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced the closing of its previously announced public offering of an aggregate of 4,000,000 of the Company's ordinary shares and accompanying warrants to purchase up to 4,000,000 of the Company's ordinary shares, at a combined public offering price of $0.65 per ordinary share and associated ordinary warrant. The ordinary warrants have an exercise price of $0.65 per ordinary share, are exercisable immediately upon issuance and will expire on the five-year anniversary of the issuance date.
Neutral
GlobeNewsWire
2 weeks ago
Lifeward Announces Pricing of $2.6 Million Public Offering
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, June 25, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced the pricing of a public offering of an aggregate of 4,000,000 of the Company's ordinary shares and accompanying warrants to purchase up to 4,000,000 of the Company's ordinary shares, at a combined public offering price of $0.65 per ordinary share and associated ordinary warrant. The ordinary warrants will have an exercise price of $0.65 per ordinary share, will be exercisable immediately upon issuance and will expire on the five-year anniversary of the issuance date. The closing of the offering is expected to occur on or about June 26, 2025, subject to the satisfaction of customary closing conditions.
Neutral
GlobeNewsWire
2 weeks ago
Administrative Law Judge Determines ReWalk Personal Exoskeleton is “Reasonable and Necessary” for Medicare Beneficiary
Decision at the highest levels of appeal in the Medicare process establishes medical necessity of the ReWalk Exoskeleton for enabling paralyzed individuals to stand and walk in everyday environments. Decision at the highest levels of appeal in the Medicare process establishes medical necessity of the ReWalk Exoskeleton for enabling paralyzed individuals to stand and walk in everyday environments.
Neutral
GlobeNewsWire
1 month ago
Lifeward Names Mark Grant as New CEO
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd.
Neutral
GlobeNewsWire
1 month ago
Lifeward to Present at Sidoti Virtual Investor Conference on May 21
MARLBOROUGH, Mass., and YOKNEAM ILLIT, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Lifeward, Ltd.
Negative
Zacks Investment Research
1 month ago
Lifeward (LFWD) Reports Q1 Loss, Lags Revenue Estimates
Lifeward (LFWD) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.73 per share a year ago.
Neutral
Seeking Alpha
1 month ago
Lifeward Ltd. (LFWD) Q1 2025 Earnings Call Transcript
Lifeward Ltd. (NASDAQ:LFWD ) Q1 2025 - Earnings Conference Call May 15, 2025 8:30 AM ET Company Participants Mike Lawless - CFO Larry Jasinski - CEO Almog Adar - VP, Finance Conference Call Participants Yale Jen - Laidlaw and Company Swayampakula Ramakanth - H.
Neutral
GlobeNewsWire
1 month ago
Lifeward Ltd. Reports First Quarter 2025 Financial Results
U.S. pipeline of ReWalk opportunities continues to build with over 120 qualified leads in process Closure of AlterG sites and resulting consolidation of resources and reduced expenditures yields improved operating expense trend Second consecutive quarter of AlterG revenue growth over 15% reflecting continued sales momentum MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd.
Neutral
GlobeNewsWire
2 months ago
Lifeward Completes Research Program with Israeli Human-Robot Interaction Consortium to Integrate Artificial Intelligence and Exoskeletons
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd.
Charts implemented using Lightweight Charts™